Website intended for a NZ health professional readership
In anticipation of GPs being able to initiate stimulant treatment for attention deficit hyperactivity disorder, psychiatrist David Codyre looks at the minimum assessment required for diagnosis
1. Song P, Zha M, Yang Q, et al. The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. J Glob Health 2021;11:04009.
2. Larsen R. ‘A risk of over-diagnosing ADHD’, leading NZ psychiatrist warns. RNZ, 20 November 2024.
3. Pharmac. Pharmac funds new medicine and removes renewal criteria for ADHD and narcolepsy treatments. 11 November 2024.
4. Pharmac. Proposal to change the regulatory and funding restrictions for stimulant treatments for ADHD. 17 December 2024.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
